Dermapharm Holding SE

 
DE EN
Key facts of the Company
Investor Relations

QuickCheck

Ingredients
Pharmaceutical
Ingredients

380+
Marketing authorizations
Marketing
authorisations

>1300
Revenue
Revenue EUR
2020

793.8 million
EBITDA
EBITDA EUR
2020
(unadjusted)
184.5 million

Share

Stock information
ISIN / WKN
DE000A2GS5D8 / A2GS5D
Stock exchange symbol / Reuters symbol
DMP
Type of Shares
bearer shares with no par value (Stückaktien)
First day of trading
9 February 2018
Number of Shares
53.84 million
Stock Exchanges
Regulated Market (Prime Standard) of the Frankfurt Stock Exchange
Index
since 23th September 2019
Analysts
Charlotte Friedrichs, Joh. Berenberg, Gossler & Co. KG
Daniel Wendorff, Commerzbank AG
Alexander Thiel, Jefferies International Ltd.
Dennis Berzhanin, Pareto Securities AS
Dr. Marcus Wieprecht, Stifel European Bank AG
Designated Sponsors
Joh. Berenberg, Gossler & Co. KG
Commerzbank AG
Stifel European Bank AG
Paying agent
Quirin Privatbank AG
Shareholder Structure

Shareholder Structure

Shareholder Structure

Company

Company Profile

Dermapharm - Pharmaceutical Excellence “Made in Europe”:

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

In the "Branded pharmaceuticals and other healthcare products" division, Dermapharm has more than 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

In the "Herbal extracts" division, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm's business model also includes the "Parallel import business" division that operates under the "axicorp" brand. Based on revenue, Dermapharm was among the top five parallel import companies in Germany in 2020.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, Dermapharm has continuously optimised its business over the past 30 years and sought external growth opportunities in addition to organic growth. Dermapharm is firmly committed to continuing on this profitable growth course in the future.

Boards

Management Board

Dr. Hans-Georg Feldmeier CEO, Pharmacist

Dr. Hans-Georg Feldmeier is the Chairman of the Management Board at Dermapharm. He joined the company in 2003 as project manager and was responsible for the construction of the new production facilities in Brehna. Since 2009, he has been Chief Production & Development Officer of Dermapharm. Dr. Feldmeier began his professional career in 1987 at Berlin Chemie. He played a decisive role in the modernization of the company after the fall of the Berlin Wall. In 2002, he was head of the supply center at Schering Aktiengesellschaft, Berlin.

Karin Samusch CBDO

Karin Samusch is Dermapharm’s Chief Business Development Officer. She joined the company in 1991 and has been responsible for business development, international affairs, regulatory affairs and pharmacovigilance ever since. Prior to joining Dermapharm she worked for the pharmaceutical company Dorsch GmbH and the seal producer Feodor Burgmann GmbH & Co. KG.

Dr. Jürgen Ott CMO

Since October 1, 2019 is Dr. Jürgen Ott is the Chief Marketing Officer, responsible for Marketing and Sales at Dermapharm. He holds a doctorate in chemistry and has extensive experience in the consumer goods and pharmaceutical industries. His last position since 2010 was Head of Marketing Germany, since 2014 Head of Marketing & Sales Germany and from 2017 Regional Head Central Europe at Bionorica SE, a manufacturer of herbal pharmaceuticals. Prior that he spent more than 11 years as Key Account Manager and Brand Manager at Procter & Gamble.

Hilde Neumeyer
Hilde Neumeyer CFO, CCO

Hilde Neumeyer has been Chief Financial Officer of the Dermapharm Group since July 1, 2020. She has been Chief Compliance Officer since the IPO and has developed a Governance, Risk & Compliance System as well as successfully established it within the Group. She has been working for Dermapharm in Finance and Accounting since October 1, 2000 and took over as Head of Group Accounting in 2005. Through the development of the accounting department, she has permanently and systematically adapted to new challenges and successfully integrated various acquisitions into the Group's reporting structures. Before joining the Dermapharm Group, Ms. Neumeyer worked for Novartis in accounting for 10 years.

Supervisory Board

Wilhelm Beier

Wilhelm Beier was born in Eicherscheid (Bad Münstereifel), Germany, on April 21, 1956. Starting his career in 1981, he held various positions in the pharmaceuticals industry, including a managing director of the German subsidiaries of an international pharmaceuticals manufacturer. After founding Dermapharm in 1991, Mr. Beier served as Chief Executive Officer of Dermapharm AG.

In 2017, he was appointed chairman of the supervisory board of Dermapharm.

Mr. Beier and his family hold the majority of the company's shares via Themis Beteiligungs AG.

Dr. Erwin Kern

Dr Erwin Kern was born on July 6, 1960 in Karlsruhe, Germany. In 1986, Dr. Kern completed his studies in business administration at the Ludwig Maximilian University in Munich. In 1989, he received his doctorate in economics from the University of Paderborn. Dr. Kern began his professional career in 1986 as Managing Director of HBK-Handel und Beteiligungen Kern GmbH & Co. KG. From 1991 onwards, he was a member of the management of Kies und Beton Baden-Baden GmbH & Co. Holding KG and Kies und Beton AG Baden-Baden. In 2007, Dr. Kern took over the chairmanship of the management of these companies, which he still holds today. Since 2003, he has been President of the Federal Association of the German Ready-Mixed Concrete Industry (BTB). (BTB) since 2003 and was Chairman from 2008 to 2011 and Vice Chairman from 2011 to 2013 of Construction Products Europe (CPE) (Association of European Construction Materials Manufacturers).

Dr Kern was appointed as a member of the Supervisory Board of Dermapharm Holding SE in 2017. In addition to his position at Dermapharm, Dr Kern was and is active in various companies and associations in the stone and earth industry that are not listed on the stock exchange.

Lothar Lanz

Lothar Lanz was born on October 1, 1948 in Bihlafingen, Germany. From 1969 to 1974, Mr. Lanz studied business administration at the universities of Stuttgart and Berlin and graduated with a degree in business administration. Mr. Lanz began his professional career as an audit assistant for an auditor and tax consultant in Berlin. In 1977, Mr. Lanz joined Bayerische Hypotheken- und Wechselbank AG, where he served as branch manager from 1983 to 1990. In 1991, Mr. Lanz became a member of the Board of Management of H.S.B. HYPO Service-Bank AG, Munich. In 1996, he moved to Nassauische Sparkasse, Wiesbaden, where he also became a member of the Board of Management. In the same year, Mr. Lanz moved to the then ProSieben Media AG (now ProSiebenSat.1 Media AG) as Chief Financial Officer, a post he held until 2008. From 2009 to 2014, Mr. Lanz was a member of the Executive Board of Axel Springer AG (now Axel Springer SE), where he served as Chief Financial and Operating Officer.

Mr. Lanz was appointed as a member of the Supervisory Board of Dermapharm Holding SE in 2017. In addition, he is currently Chairman of the Supervisory Board of Home 24 SE and a member of the Supervisory Board of TAG Immobilien AG and the unlisted Bauwert AG. Until 2019, he was also a member of the Supervisory Board of Axel Springer SE and Chairman of the Supervisory Board of Zalando SE.

Financial Figures
 Financial Figures    2020   2019   2018   2017   2016   2015   2014  
 Revenue  in EUR million   793.8   700.9   572.4   467.1   444.5   384.8   391.3  
 Adjusted EBITDA  in EUR million   200.7   177.6   143.4   112.9   102.7   -   -  
 Adjusted EBITDA Margin  in %   25.3   25.3   25.1   24.2   23.1   -   -  
 Unadjusted EBITDA  in EUR million   184.5   168.5   139.6   110.2   102.7   84.7   72.4  
 Unadjusted EBITDA Margin  in %   23.2   24.0   24.4   23.6   23.1   22.0   18.5  
 Operating income  in EUR million   136.9   119.5   107.5   92.1   86.8   43.3   60.8  
 Earnings before taxes  in EUR million   125.3   110.1   104.2   88.0   82.9   55.3   35.5  
 Profit or (loss) for the period  in EUR million   85.9   77.8   75.2   77.7   77.0   52.4   33.2  
 Earnings per share  in EUR   1.59   1.43   1.41   1.56   1.54   -   -  
 Dividend  in EUR   0.88   0.80   0.77   -   -   -   -  
 Balance sheet  in EUR million   1,224.4   1,044.9   704.6   415.3   311.7   296.7   330.6  
 Equity  in EUR million   324.6   284.5   256.1   73.7   60.8   44.4   34.0  
 Equity ratio  in %   26.5   27.2   36.3   17.7   19.5   15.0   10.3  
 Cash and cash equivalents  in EUR million   120.3   115.0   212.5   6.3   3.8   2.8   11.6  
 Net debt  in EUR million   486.8   465.4   95.2   258.5   173.7   189.7   210.8  

 

Picture Archive
Locations

IR Contact & Events

IR Contact

IR Contact

If you have any further questions, please do not hesitate to contact us. You can contact us via e-mail or directly by telephone. In addition, we offer you the opportunity to join our IR news service in order to receive information from Dermapharm Holding SE promptly. Furthermore, all current dates can be found in the financial calendar.

Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany

Contact person:
Britta Hamberger
Investor Relations & Corporate Communications
Phone: +49 (0) 89 641 86 233
Fax: +49 (0) 89 641 86 165

IR News Service

IR News Service

We are happy to include you in our news service! Please simply fill in the form below and you will receive information on the subject Investor Relations.
Financial Calendar

30 March 2021: Publication of preliminary figures for the 2020 annual financial statements

13 April 2021: Publication of annual financial statements 2020

18 May 2021: Publication of quarterly statement (reporting date Q1 2021)

23 June 2021: Annual General Meeting

24 August 2021: Publication of preliminary figures for the 2021 half-year

07 September 2021: Publication of the 2021 half-year report

16 November 2021: Publication of quarterly statement (reporting date Q3 2021)

Corporate Governance

Voting Rights Notification

2020-10-15 | Voting Rights Announcement of Wilhelm Beier

2018-02-13 | Voting Rights Announcement of Wilhelm Beier

2018-02-09 | Voting Rights Announcement of Wilhelm Beier

Directors‘ Dealings

2020-02-02 | Announcement of Hilde Neumeyer

2020-11-18 | Announcement of Hilde Neumeyer

2020-10-15 | Announcement of Themis Beteiligungs-Aktiengesellschaft

2020-10-14 | Announcement of Hilde Neumeyer

2019-08-08 | Announcement of Karin Samusch

2019-07-01 | Announcement of Themis Beteiligungs-Aktiengesellschaft

2018-03-13 | Announcement of Themis Beteiligungs-Aktiengesellschaft

2018-02-09 | Announcement of Themis Beteiligungs-Aktiengesellschaft

2018-02-09 | Announcement of Themis Beteiligungs-Aktiengesellschaft

Statement of Compliance

Updated Declaration of Conformity 2021 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Updated Declaration of Conformity 2020 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Updated Declaration of Conformity 2019 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Updated Declaration of Conformity 2018 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Declaration of Conformity 2018 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Other Documents

Articles of Association of Dermapharm Holding SE (German)

Rules of Procedure of Dermapharm Holding SE

Compliance

Code of Conduct

Compliance Manual (Code of Conduct)

Weitere Dokumente

UK Modern Slavery Act Statement 2020

UK Modern Slavery Act Statement 2019

Annual General Meeting

Documents

The Annual General Meeting of Dermapharm Holding SE, based in Grünwald, Munich district, will take place on June 17, 2020 at 10:00 a.m. as a virtual general meeting in the company's premises, Lil-Dagover-Ring 7, 82031 Grünwald.

Dermapharm Holding SE ‒ Annual Report 2019 including the consolidated financial statements, the combined management report, the explanatory report of the Management Board on the disclosures pursuant to Sections 289a (1), 315a (1) German Commercial Code (HGB) and the report of the Supervisory Board for financial year 2019

Dermapharm Holding SE - Individual financial statement 2019 according to German Commercial Code (HGB) including the adopted annual financial statements of Dermapharm Holding SE (German)

Invitation including the agenda and the disclosures according to § 124a sentence 1 no. 2 and 4 AktG (German)

Report of the Supervisory Board for the financial year 2019 (German)

Articles of Association of Dermapharm Holding SE (German)

Explanation of the Shareholders' Rights 2020 (German)

Additions to the agenda: There are currently no requests by shareholders to put additional items on the agenda that need to be published.

Countermotions and election nominations: There are currently no countermotions and/or election nominations by shareholders that need to be published.

Voting Results

Voting results of the Annual General Meeting 2020

Presentation

Dermapharm Holding SE – AGM 2020 Presentation

Archive

Annual General Meeting 2019

Dermapharm Holding SE ‒ Annual Report 2018 including the consolidated financial statements, the combined management report, the explanatory report of the Management Board on the disclosures pursuant to Sections 289a (1), 315a (1) German Commercial Code (HGB) and the report of the Supervisory Board for financial year 2018

Dermapharm Holding SE - Individual financial statement 2018 according to German Commercial Code (HGB) including the adopted annual financial statements of Dermapharm Holding SE (German)

Invitation including the agenda and the disclosures according to § 124a sentence 1 no. 2 and 4 AktG (German)

Report of the Supervisory Board for the financial year 2018

Articles of Association of Dermapharm Holding SE (German)

Explanation of the Shareholders' Rights 2019 (German)

Voting results of the Annual General Meeting 2019

Dermapharm Holding SE – AGM 2019 Presentation

Annual General Meeting 2018

Dermapharm Holding SE - Annual report 2017 including the consolidated financial statements, the management report on the Group’s situation and the report of the Supervisory Board each for the financial year 2017

Dermapharm Holding SE – Individual financial statement according to German Commercial Code (HGB) (German)

Invitation including the agenda and the disclosures according to § 124a sentence 1 no. 2 and 4 AktG

Report of the Supervisory Board (as of May 18, 2018)

Articles of Association of Dermapharm Holding SE (German)

Explanation of the Shareholders' Rights 2018 (German)

Dermapharm AGM 2018 – Voting Results

Dermapharm Holding SE – AGM 2018 Presentation

Publications

Corporate News

2021-05-18 | Dermapharm Holding SE: accelerated EBITDA growth in Q1 2021

2021-04-30 | Dermapharm Holding SE: Federal Minister of Health Jens Spahn joins opening ceremony for vaccine manufacturing facility at subsidiary Allergopharma GmbH & Co. KG

2021-04-13 | Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures

2021-03-30 | Dermapharm posts growth despite COVID-19 pandemic – consolidated revenue and EBITDA continue to rise

2021-02-12 | Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021

2020-11-16 | Dermapharm Holding SE continues on its growth course in third quarter of 2020

2020-09-30 | Dermapharm Holding SE – subsidiary axicorp GmbH breaks ground for a new building near Frankfurt/Main

2020-09-10 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine

2020-09-09 | Dermapharm publishes Half-Year Financial Report 2020 and confirms growth course despite corona pandemic

2020-08-21 | Dermapharm remains on growth course despite corona pandemic in the first half of 2020

2020-06-17 | Dermapharm Holding SE: Annual General Meeting approves dividend payout of EUR 0.80 per share

2020-05-19 | Growth in the first quarter of 2020 despite the corona pandemic

2020-04-08 | Dermapharm confirms profitable growth in 2019 and presents positive outlook for 2020 despite corona

2020-03-31 | Dermapharm successfully acquires Allergopharma

2020-03-25 | Dermapharm continues its profitable growth in 2019

2020-02-19 | Dermapharm Holding SE to acquire Allergopharma

2020-02-05 | Dermapharm Holding SE opens new logistics center in Brehna

2019-11-20 | Dermapharm Holding SE continues to drive the company’s growth in the third quarter of 2019

2019-09-12 | Dermapharm confirms profitable growth in first half of 2019

2019-08-23 | Dermapharm continues on its profitable growth course in first half of 2019

2019-07-29 | Dermapharm Holding SE: Dr. Jürgen Ott named new CMO

2019-07-01 | Dermapharm Holding SE with increased free float

2019-06-06 | Dermapharm Holding SE acquires a stake in fitvia

2019-06-04 | Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.77 per share

2019-05-21 | Dermapharm Holding SE: First quarter of 2019 characterized by profitable growth

2019-04-26 | Dermapharm to expand capacities at its main production site in Brehna

2019-04-17 | Fiscal year 2018

2019-04-03 | Preliminary figures for fiscal year 2018

2019-03-04 | Dermapharm Holding SE acquires stake in cannabis producer for pharmaceutical applications

2019-02-21 | Dermapharm continues to drive development of new products

2019-01-23 | Dermapharm continues expansion course

2018-11-20 | Third Quarter 2018

2018-11-18 | Signing of contract for the acquisition of EUROMED S.A.

2018-11-16 | Dermapharm takes legal action against approval of a competitor product

2018-09-12 | First Half-Year 2018

2018-08-21 | Preliminary figures for the first half of 2018

2018-06-26 | AGM 2018

2018-05-18 | First Quarter 2018

2018-04-27 | Fiscal year 2017

2018-04-09 | Preliminary Figures 2017

2018-02-08 | Pricing

2018-01-26 | IPO Details

2018-01-15 | INTENTION TO FLOAT

Ad Hoc News

2021-02-12 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccineproduction to make a high double-digit million € contribution to sales in 2021

2020-09-10 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE

2020-02-19 | Dermapharm Holding SE: Acquisition of Allergopharma

2019-06-06 | Dermapharm Holding SE acquires a stake in fitvia

2019-03-04 | Dermapharm Holding SE acquires stake in cannabis producer for pharmaceutical applications

2018-11-18 | Signing of contract for the acquisition of EUROMED S.A.

2018-02-08 | Pricing

Financial Reports

Dermapharm Holding SE - Interim Statement first quarter 2021

Dermapharm Holding SE - Individual Financial Statement 2020 according to German Commercial Code (HGB) (German)

Dermapharm Holding SE - Annual report 2020

Dermapharm Holding SE - Interim Statement third quarter 2020

Dermapharm Holding SE - Half-year Financial Report 2020

Dermapharm Holding SE - Interim Statement first quarter 2020

Dermapharm Holding SE - Individual Financial Statement 2019 according to German Commercial Code (HGB) (German)

Dermapharm Holding SE - Annual report 2019

Dermapharm Holding SE - Interim Statement third quarter 2019

Dermapharm Holding SE - Half-year Financial Report 2019

Dermapharm Holding SE - Interim Statement first quarter 2019

Dermapharm Holding SE - Individual financial statement 2018 according to German Commercial Code (HGB) (German)

Dermapharm Holding SE - Annual report 2018

Dermapharm Holding SE - Interim Statement third quarter 2018

Dermapharm Holding SE - Half-year Financial Report 2018

Dermapharm Holding SE - Interim Statement first quarter 2018

Dermapharm Holding SE - Individual financial statement according to German Commercial Code (HGB) (German)

Dermapharm Holding SE - Annual report 2017

Dermapharm Holding SE - IFRS Financial Statements as of September 30,2017

Dermapharm AG - IFRS Consolidated Financial Statements and Group Management Report as of December 31, 2016

CSR Report

Dermapharm Holding SE - CSR Report 2020

Dermapharm Holding SE - CSR Report 2019

Dermapharm Holding SE - CSR Report 2018

Presentations

Dermapharm Holding SE - Q1/2021 Presentation

Dermapharm Holding SE - FY 2020 Presentation

Dermapharm Holding SE - Q3/2020 Presentation

Dermapharm Holding SE - H1/2020 Presentation

Dermapharm Holding SE - Q1/2020 Presentation

Dermapharm Holding SE - FY 2019 Presentation

Dermapharm Holding SE - Q3/2019 Presentation

Dermapharm Holding SE - H1/2019 Presentation

Dermapharm Holding SE - Q1/2019 Presentation

Dermapharm Holding SE - FY 2018 Presentation

Dermapharm Holding SE - Q3/2018 Presentation

Dermapharm Holding SE - H1/2018 Presentation

Dermapharm Holding SE - Q1/2018 Presentation

Other Documents

Prospectus